June 8, 2007
LabCorp has entered into a license agreement with Veridex LLC to commercialize nucleic acid testing technology for detecting the presence of methylated GST-Pi, a key tissue marker in prostate cancer.
LabCorp is the first full-service, national clinical laboratory in the US to license this new technology.
When utilized in combination with conventional histopathology testing, an assay quantifying the level of methylated GST-Pi may provide a more sensitive and accurate detection of prostate cancer than histology alone. The assay LabCorp plans to offer is anticipated to be useful for biopsies with suspicious histopathology, and for patients who have elevated prostate specific antigen values with biopsy findings that are repeatedly negative.
